Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Madrigal Pharmaceuticals (MDGL) FCF Margin: 2009-2025

Historic FCF Margin for Madrigal Pharmaceuticals (MDGL) over the last 10 years, with Sep 2025 value amounting to 27.50%.

  • Madrigal Pharmaceuticals' FCF Margin rose 13649.00% to 27.50% in Q3 2025 from the same period last year, while for Sep 2025 it was -21.82%, marking a year-over-year increase of 60614.00%. This contributed to the annual value of -253.72% for FY2024, which is 281594.00% down from last year.
  • Madrigal Pharmaceuticals' FCF Margin amounted to 27.50% in Q3 2025, which was up 224.37% from -22.11% recorded in Q2 2025.
  • Over the past 5 years, Madrigal Pharmaceuticals' FCF Margin peaked at 12,573.96% during Q2 2022, and registered a low of -92,623.08% during Q4 2021.
  • For the 3-year period, Madrigal Pharmaceuticals' FCF Margin averaged around 1,215.82%, with its median value being 27.50% (2025).
  • In the last 5 years, Madrigal Pharmaceuticals' FCF Margin slumped by 7,990,155bps in 2021 and then skyrocketed by 10,228,380bps in 2022.
  • Madrigal Pharmaceuticals' FCF Margin (Quarterly) stood at -92,623.08% in 2021, then skyrocketed by 10,228,380bps to 9,660.73% in 2022, then slumped by 762,172bps to 2,039.01% in 2023, then plummeted by 214,033bps to -101.32% in 2024, then skyrocketed by 13,649bps to 27.50% in 2025.
  • Its FCF Margin was 27.50% in Q3 2025, compared to -22.11% in Q2 2025 and -64.77% in Q1 2025.